This site is intended for healthcare professionals

Bayer to sell men’s health product Nebido to Grünenthal.

Read time: 1 mins
Published:14th Jul 2022

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer’s men’s health product Nebido (testosterone undecanoate), for a purchase price totaling up to 500 million Euro.

Nebido for the treatment of male hypogonadism (testosterone deficiency) is available in over 80 countries since 2004. In 2021, the product contributed sales of 117 million Euro to Bayer’s overall sales of more than 44 billion Euro.

Grünenthal will acquire the global product rights to Nebido for an upfront purchase price of up to 500 million Euro, subject to customary closing adjustments, including the contract business in the U.S, where Endo Pharmaceuticals has licensed the compound under the name Aveed from Bayer. The transaction is expected to close by the end of 2022, pending the satisfaction of customary closing conditions, including approval by the competition authorities.

Condition: Testosterone Deficiency
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.